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In many clinical experiments, particularly in randomized clinical trials, the sample sizerequired needs to be assessed and justified. For calculating a clinical trial’s sample size,assumptions have to be made regarding the clinical trial’s outcome data. These assumptions
are based on prior clinical trials or merely on expert knowledge and always subject to some degree
of uncertainty. To cope with this uncertainty in sample size estimation, adaptive designs were
developed to re-estimate the sample size within a running trial. Especially adaptive designs for
blinded sample size re-estimation, also referred to as non-comparative adaptive designs, have
gained popularity, as these generally do not require an adjustment of the significance level to
maintain type I error rates.
In the first part of this thesis, we will consider developing sample size re-estimation methods
for longitudinal overdispersed count data. As a first step, such data is modeled by a negative
binomial counting process, and techniques for inference, sample size estimation and sample size
re-estimation are provided. In a second step, presented methods are extended to handle time
trends, which may occur during the course of a clinical trial. These trends are modeled by a
gamma frailty model, for which inference, sample size estimation and sample size re-estimation
techniques are also described in detail. As an application, we consider lesion counts measured by
magnetic resonance imaging (MRI), which play an important role in phase II multiple sclerosis
(MS) trials for measuring disease progression. These lesion counts are generally overdispersed
and often measured multiple times per patient during a running trial, therefore resembling the
statistical model. Methods are kept general to allow for applications outside of MS, whenever
similar data arise, and shown to preserve type I error rates while correcting the sample size, such
that a desired power level is reached, in extensive simulation runs.
The second part of this thesis will consider univariate negative binomial data with baseline
covariates. For example, such data arise in MS when the total number of lesions at the end of a
clinical trial, corrected for the number of lesions at baseline or other baseline variables, is taken
as an endpoint. Developed sample size re-estimation techniques are also shown to preserve type
I error rates while correcting the sample size such that a desired power level is reached. The
summarized results are made available as R-functions and extend current methodology in the
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1.1 Adaptive Designs for Sample Size Re-estimation
When planning clinical trials, the sample size has to be justified for ethical and economical
reasons. On the one hand, if a sample size is too low, the power for rejecting the null hypothesis is
too low and the planned clinical trial may fail to empirically prove the clinical objective, requiring
further clinical trials in the follow-up. On the other hand, a too high sample size will burden
unnecessarily many patients with undergoing the clinical trial, potentially putting them at risk
for adverse events. Furthermore, a larger trial will likely take more time to complete, delaying the
introduction of a potentially safe and efficacious treatment into the market, and requiring more
resources in the process. Therefore, attaining a proper sample size for a clinical trial is a necessary
task. Formulas for calculating the sample size depend on many different aspects, such as trial
design, intended power, significance level for hypothesis testing, but also the minimal clinically
relevant effect size and nuisance parameters, which includes the event rate in the control arm
and shape parameter, when considering negative binomial count data, or the variability in groups,
when considering continuous outcomes [40].
While some of these influencing aspects, such as intended power and significance level, can be
determined when planning a clinical trial, nuisance parameters can only be assessed from other
sources, such as previous clinical trials. However, assessing nuisance parameters from previous
clinical trials can be a difficult task. Previous clinical trials may not report required nuisance
parameters or are insufficiently comparable to the planned trial, as they do not consider the same
patient population or differ in trial design. In some cases, for example when the endpoint is being
studied for the first time, previous trials may not even exist in the first place [13]. Therefore,
the nuisance parameters assumed from results of previous clinical trials are always subject
to some degree of uncertainty. Consequently, the sample size calculated with these nuisance
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parameters is uncertain as well. To overcome this uncertainty in sample size estimation, sample
size re-estimation procedures have been proposed, which re-estimate the sample size based
on estimates for nuisance parameters within a running trial, ensuring adequate power while
maintaining statistical rigor of trial results [39, 51, 53].
Following the introduction above, sample size re-estimation aims to change the planned sample
size within a running trial, making it a type of adaptive design. In the guideline Adaptive Designs
for Clinical Trials of Drugs and Biologics [21], the United States Food & Drug Administration
(FDA) distinguishes between adaptive designs based on comparative data and adaptive designs
based on non-comparative data. Sample size re-estimation can be done both on comparative
data, i.e. using the group assignment for estimation, and on non-comparative data, i.e. without
knowledge of the group assignment. Sample size re-estimation based on comparative data
includes designs which adapt the sample size based on an interim result of the effect size, also
called unblinded sample size re-estimation. Such designs are employed when there is considerable
uncertainty about the true treatment effect size, but require proper adjustment of the significance
level, following one of many different methods [9, 12, 17, 18, 20, 48] as they can inflate the type I
error probability. For example, Proschan and Hunsberger [54] have shown that the type I error
probability can be more than double the significance level if no proper adjustment is employed.
This stands in contrast to blinded sample size re-estimation, which, as a non-comparative adaptive
design, generally has no effect or a limited effect on the type I error probability and therefore does
not require an adjustment of the significance level [21]. Another type of re-estimation method
lies in between these two categories, in that they re-estimate the sample size based on nuisance
parameters attained from comparative data, but without an interim estimated treatment effect.
These methods are also referred to as partially blinded or partially unblinded [51].
Blinded sample size re-estimation procedures, which we will focus on, estimate nuisance para-
meters required for calculating the sample size based on non-comparative data from a running
trial, assuming a relevant effect size used in the planning phase to be present. Estimates for
nuisance parameters are then used to calculate the sample size anew and the sample size is
adjusted for incorrect assumptions met at the initial sample size calculation. Procedures for
blinded sample size re-estimation have been developed for numerous outcome types, including
normally distributed data [29], normally distributed data with covariates [23, 65], dichotomous
outcomes [24], Poisson distributed count data and overdispersed count data [15, 25, 26, 56, 57].
1.2 Clinical Trials in Multiple Sclerosis
As an application of blinded sample size re-estimation for longitudinal count data, we will consider
clinical trials in multiple sclerosis (MS). MS is an autoimmune disorder affecting the brain and
spinal cord by damaging the insulating covers of nerve cells. It is the most common inflammatory
neurological disorder in young adults with approximately 2.2 million affected people worldwide in
2
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2016 [63]. To this day, no known cure for MS exists, making it an intense field of medical research.
Disease progression is often experienced as an increased occurrence of related symptoms, such as
fatigue, spasticity, resulting in walking difficulties, and vision problems. These symptoms can
occur either in isolated attacks (relapsing and remitting) or steadily increase in severity over
time (progressive) [43]. Depending on the pattern of progression experienced by affected patients,
the National Multiple Sclerosis Society defined four distinct disease-courses in 1996 and updated
these in 2013 [42, 43]:
• Clinically Isolated Syndrome (CIS)
• Relapsing-Remitting Multiple Sclerosis (RRMS)
• Primary Progressive Multiple Sclerosis (PPMS)
• Secondary Progressive Multiple Sclerosis (SPMS)
CIS is the occurrence of symptoms that could be MS, but have yet to fulfill dissemination
criteria in time [47]. Once current MS diagnostic criteria are fulfilled, a patient with CIS is
categorized to RRMS. Patients with RRMS experience active phases with increased MRI activity
and occurrences of relapses, as well as inactive phases with less signs of symptoms. PPMS and
SPMS are two distinct progressive forms of MS, in which symptom severity increases gradually
in time. While it is important to distinguish different types of MS for treatment, and therefore
also when designing clinical trials for specific patient types, the underlying type of MS can not be
determined with full certainty and is often assessed in retrospect by considering the patient’s
medical history [43].
In phase III confirmatory trials, the occurrence of relapses, as a temporary worsening of neuro-
logical symptoms, e.g. summarized as annualized relapse rates, are clinical endpoints in RRMS,
whereas endpoints in PPMS or SPMS include measures of disability worsening, e.g. based on
assessments of the expanded disability status scale (EDSS) [62]. For phase II trials, however,
these endpoints are not feasible as they require a high number of subjects and long observation
period to discover significant treatment effects. Therefore, numerous surrogate parameters, such
as T2-hyperintense lesions, Gadolinium-enhancing T1 lesions and whole brain atrophy, have
been established to monitor disease progression in smaller and shorter phase II trials [62] and
used in numerous clinical trials [8, 11, 28, 37, 38]. We will focus on the count measures, i.e.
Gadolinium-enhancing T1 lesion, also referred to as ‘black holes’, and T2-hyperintense lesions,
also referred to as ‘white spots’. These measures are inter-related but different from a medical
perspective. Gadolinium-enhancing T1 lesion counts may arise from severe chronic demyelination,
inflammation, permanent axonal damage and gliosis through MS. T2-hyperintense lesions can
show the total number of lesions as they are a marker of past injury, which only rarely disappear
completely [14]. Lesion counts can be measured at several time points during a running trial. For
example, Chataway et al. [11], who conducted a phase II clinical trial to examine the efficacy of
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simvastatin in progressive MS, examined T2-hyperintense lesion counts at baseline, 12 months
after admission and 24 months after admission, resulting in longitudinal count data.
1.3 Considerations for Statistical Modeling
Different possibilities for modeling longitudinal count data exist. The choice of the statistical
model we consider is based on two characteristics observed in real data. The first characteristic
we observe, is that counts at each time point are overdispersed, i.e. the variance of marginal
observations is substantially higher than their mean. For example, Tubridy et al. [61] measure
an overdispersion of 3.37 when considering lesions of RRMS patients at month one (mean lesion
rate of 1.61 and variance of 5.44). Therefore, a model which allows for overdispersed marginal
observations is required. The second characteristic is that observations between different time
points are correlated, e.g. Tubridy et al. [61] measure a correlation of 0.48 between month one
and month two lesion counts of RRMS patients. Therefore, any statistical model considered
should account for dependencies observed between different time points. Figure 1.1 displays the






































Figure 1.1: Number of enhancing lesions attained from serial brain MRI in relapsing-remitting
multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS). [61]
Although modeling correlation between continuous observations is well explored, this task is
incomparably more difficult for count data, as no natural multivariate extension of the Poisson or
negative binomial distribution exists. Many different approaches for modeling longitudinal count
4
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data have been developed, including inter time series as Markov Chains [16, 34, 35] parametric
models [2, 3, 31], general classes of estimating equations [27, 36], random effects and latent
process approaches [10, 19, 32, 33]. Here, we present two different models, which both allow
for modeling dependencies between overdispersed count data. Each of these models has their
strengths and weaknesses, which we will acknowledge and discuss. The first statistical model
used to model lesion counts is a negative binomial integer valued autoregressive process of
first order, also NB-INAR(1) model, introduced by McKenzie [46] and re-parametrized for our
purposes. The second model we present, is a gamma frailty model, introduced by Henderson and
Shimakura [33] and extended by Fiocco et al. [19].
1.4 Outline of the Presented Research
The main purpose of the presented research is to extend the methodology developed for blinded
sample size re-estimation of univariate overdispersed count data developed by Friede and
Schmidli [25, 26] and Schneider et al. [56, 57] to a multivariate setting. Friede and Schmidli
developed blinded sample size re-estimation procedures for comparing two groups with univariate
Poisson or negative binomial distributed outcomes. Schneider et al. extended these procedures
to cope with incomplete observations at the time point of the interim analysis, as well as time
trends within response rates. Extending these methods will allow for sample size re-estimation
in clinical trials with longitudinal count end points, observed multiple times at fixed time points.
The developed methods are each presented in a similar structure. We begin by introducing and
adapting the underlying statistical model. The step of statistical modeling is followed by deriving
procedures for statistical inference, from which sample size formulas can be calculated. These
sample size formulas are then studied to develop blinded sample size re-estimation techniques.
Finally, the performance of the developed sample size re-estimation techniques is examined in
simulations. The procedures are shown to properly adjust the sample size of clinical trials while
not inflating the type I error probability and therefore fulfilling regulatory requirements. The
developed methods are further demonstrated on real data examples and an implementation in R
[55] is given.
The outlined research is presented in three different papers and has been published in peer-
reviewed journals:
• Asendorf, T, Henderson, R, Schmidli, H, Friede, T. (2019). Modelling and sample size
reestimation for longitudinal count data with incomplete follow up. Statistical Methods in
Medical Research, 28(1), 117-133. https://doi.org/10.1177/0962280217715664
• Asendorf, T, Henderson, R, Schmidli, H, Friede, T. (2019) Sample size re-estimation for
clinical trials with longitudinal negative binomial counts including time trends. Statistics
in Medicine, 38, 1503-1528. https://doi.org/10.1002/sim.8061
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• Zapf, A, Asendorf, T (shared first authorship), Anten, C, Mütze, T, Friede, T. (2020). Blinded
sample size reestimation for negative binomial regression with baseline adjustment. Statis-
tics in Medicine, 39, 1980-1998. https://doi.org/10.1002/sim.8525.
As a first attempt of modeling longitudinal count data, the first paper considers the NB-INAR(1)
model for blinded sample size re-estimation, which easily allows for incorporating incomplete
follow up data. The second paper uses a gamma frailty model to allow for trend formulations
within clinical trials and further evaluates the methodology for non-inferiority trials. The third
paper explores the utilization of covariates in blinded sample size re-estimation, but in the












The negative binomial integer valued autoregressive process of first order (NB-INAR(1) model)
presented here, and used in deriving the proposed adaptive designs, is a variation of the binomial
thinning model from McKenzie [46] and Al-Osh and Alzaid [1]. The NB-INAR(1) model allows for
generating observations which marginally follow a negative binomial distribution, while at the
same time allowing for autoregressive dependencies of first order between different observations.
This is achieved using an operation called binomial thinning, formally introduced by Steutel
and van Harn [60]. Let X be some positive random integer and Bk(p) i.i.d. Bernoulli distributed
random variables with parameter p, i.e. P(Bk(p)= 1)= p, independent of X for all k ∈N. Then,
the binomial thinning operator is defined as




From the definition it becomes clear that the random variables X and X ◦ p are positively
correlated for p ∈ (0,1]. Furthermore, both X and X ◦ p are integers. Therefore binomial thinning
is a viable operation for generating dependent count data, which we will make use of. Let X (t)i j
denote the observation of patient j in group i at time point t, where i = E,C (experiment and
control group), j = 1, . . . ,ni and t = 1, . . . ,T. Then the statistical model is given by
(2.2) X (t)i j = X (t−1)i j ◦U (t)i j +W (t)i j for t = 2, . . . ,T, j = 1, . . . ,ni, i = E,C,
where the random variables observed at the first time point are defined to be negative binomial dis-
tributed with mean λi and shape parameter η, i.e. X (1)i j
i.i.d.∼ NB(λi,η). The parameter used for bi-
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nomial thinning is now a random variable U (t)i j
i.i.d.∼ Beta (aη, (1−a)η) and the resulting term from
binomial thinning is added to an independent random variable W (t)i j
i.i.d.∼ NB ((1−a)λi, (1−a)η).
In Appendix A of Asendorf et al. [6], it was proven that observations X (t)i j then follow a negative
binomial distribution with mean λi and shape parameter η for t = 1, . . . ,T. Further, two observa-
tions from the same patient were shown to be correlated with Cov(X (t)i j , X
(s)
i j )= a|s−t| · (λi +λ2i /η)
(Appendix B, Asendorf et al. [6]). Therefore, we could model a marginal negative binomial distri-
bution and at the same time have an autoregressive dependency structure of first order between
time points, a typical assumption in time series analysis. In the following calculations we will
further denote the dependency parameter ρ, defined as







The parameter ρ is essentially a geometric sum of the correlation parameter a and will ease the
notation in following calculations.
2.1.1 Statistical Inference
Within the NB-INAR(1) model, the main interest lies in testing differences of means between
groups. More specifically, we will be testing for differences between groups by using the rate ratio
θ =λE/λC, where the hypothesis of interest is given by
(2.4) H0 : θ ≥ 1 vs. H1 : θ < 1.
For testing the null hypothesis H0, we derive a Wald-type test statistic Z using moment estimators
λ̂i, ρ̂ and 1λi + 1η for λi, ρ and 1λi + 1η , respectively. Using the delta method in conjunction with the
central limit theorem, it was proven that















) approx∼ N(0,1) under H0.
It is worthwhile to point out, that for the derivation of the test statistic moment estimators were
used. This approach is similar to an approach taken by Friede and Schmidli [25] for the case of
univariate overdispersed Poisson counts, and chosen because the resulting Wald-type statistic
is of a closed form and therefore allows for an explicit sample size formula. An approach with
maximum likelihood estimates would have required an explicit formula of the inverse Fisher
information, which could not be attained due to the complex likelihood structure, especially
for multiple time points. Therefore, using a maximum likelihood approach would only have
been feasible with numeric calculations, giving less insight on the influence of specific nuisance
8
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in estimates for η and λi. The reason is, that the moment estimator for η can be negative in the
case of underdispersed data. While underdispersed lesion counts are not probable in MS, these
can occur occasionally during simulation runs and halt calculations. The employed estimators
themselves are described in more detail within Asendorf et al. [7].
Using the derived test statistic Z and its approximate normal distribution, the required sample














where nC denotes the required sample size of the control group, k = nE/nC denotes the allocation
ratio, θ∗ the assumed effect under alternative or clinically relevant effect size, and λ= (kλE +
λC)/(k+1) the overall rate. The closed form sample size formula allows us to study the influence
of certain parameters on the sample size. For example, if the correlation parameter a is equal to
1, then ρ is equal to 1 and increasing the number of time points T has no effect on the required
sample size. In that case, the sample size formula reduces to the simpler case of a two group
comparison and one time point, as considered by Friede and Schmidli [26]. On the other end, if
a = 0, the parameter ρ is equal to 1/T and increasing the number of time points is equivalent
to increasing the sample size. The sample size formula was shown to be accurate and hold the
desired power in a number of different settings, described in Table 2 of Asendorf et al. [6].
2.1.2 Blinded Sample Size Re-estimation
To perform a blinded sample size re-estimation, it is necessary to estimate all nuisance parameters
influencing the sample size in a blinded manner. To accomplish this task, we will estimate the
nuisance parameters using a likelihood approach assuming that the blinded observations follow
a mixture distribution of both groups with known weights. This approach is an alternative to
the so called lumping approach, which assumes data to be from a common distribution, for
example employed in Friede and Schmidli [25, 26] and discussed by Proschan [52]. The likelihood
necessary to achieve a blinded estimation of nuisance parameters λ, a and η is given by













(·) is the marginal probability function of the first observation and fX (t+1)j |X (t)j (·) describes
the conditional probabilities of subsequent observations, exploiting the Markov structure of the
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and




























where B(x, y)=Γ(x)Γ(y)/Γ(x+ y) denotes the beta function, Γ(x)= ∫ ∞0 tx−ye−tdt the gamma func-
tion and PNB(x,λ,η) the probability function of the negative binomial distribution with mean λ
and variance λ+λ2/η. Note, that the shape parameter is assumed to be equal in both groups. To
perform a sample size re-estimation within a running trial, the nuisance parameters are esti-
mated from the likelihood (2.8), assuming that the effect size is equal to the assumed effect size,
and plugged into the sample size formula from (2.6) to attain a blinded sample size re-estimate.
From a practical perspective, however, another issue appears. Because recruitment capacity
of centers is limited and patient numbers are therefore accumulated over time, it is common
for recruitment in prospective longitudinal trials to follow a certain scheme. This results in















Figure 2.1: Possible recruitment scheme of a clinical trial with 6 month follow-up per patient.
Each line represents the observation time of an individual patient with interim analysis planned
12 months after trial onset.
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Consequently, some data from patients are available although their follow-up has not been
completed. This data can be incorporated into the analysis by replacing the fixed final time point
T by a subject-specific final time points T j for j = 1, . . . ,nE +nC in Equation (2.7). Depending on
the proportion of incomplete data at interim, incorporating incomplete data can substantially
reduce the variability of the sample size estimate as shown in Asendorf et al. [6], see in particular
Table 4.
2.1.3 Numerical Evaluation of Type I Error Rate and Power
The performance of the proposed BSSR procedure, especially in comparison to the fixed design,
was thoroughly investigated for settings realistic for lesion counts in multiple sclerosis. First, the
type I error of an experiment with the re-estimated sample size and that of a fixed design was
compared. The fixed sample size was calculated assuming an overall rate of λ= 2, correlation
parameter of a = 0.5 and shape parameter of η = 1 (equivalent to a variance of 6), resulting
in a required sample size of 165 patients per group to prove an alternative of θ∗ = 0.8 with a
power of 80% at one-sided significance level α= 2.5%. The data, however, was generated with
different nuisance parameters and no effect present. A comparison between the fixed design and
an experiment with the re-estimated sample size in terms of type I error is given in Asendorf
et al. [6] Table 3. The BSSR does not show any form of type I error inflation in the regarded
settings. Although this result is somewhat expected, as sample size re-estimation methods for
non-comparative designs generally have no or a limited effect on the type I error rate [21], in
certain situations an inflation of the type I error rate can be observed, e.g. in Friede and Kieser
[22]. For this reason, the type I error rate always needs to be examined when introducing such
designs.
To investigate the effect of the BSSR procedure on the power of a trial, a simulation study was
performed for complete observations in which data was simulated with nuisance parameters
different to those at the initial planning phase, altering each nuisance parameter one by one.
Then, half of the data was taken for a blinded sample size re-estimation and the power was
compared between recruiting the re-estimated sample size and continuing with the initially
planned sample size. Simulation results are displayed in Figure 2.2.
11
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Overall Rate Correlation Parameter Shape Parameter









Figure 2.2: Simulated power of BSSR and fixed design with true nuisance parameters (x-axis)
altered one by one. Underlying Model: NB-INAR(1). Each parameter combination was simulated
10,000 times.
While the fixed design assumed nuisance parameters λ= 2, a = 0.5 and η= 1, true parameters
were simulated to be different one by one, with the overall rate varying between 1.5 and 2.5,
the correlation parameter between 0.3 and 0.7 and the shape parameter between 0.5 and 1.5.
Simulation results revealed, that the re-estimated sample size achieved the intended power, while
the fixed design (with the initially planned sample size) was either over- or underpowered, apart
from the situation in which the true parameters and assumed nuisance parameters coincide.
2.1.4 Software Implementation and Availability of Methods
The presented methods have been implemented within the R-package spass (study planning and
adaptation of sample size [5]) and made available on CRAN. The package contains functions for
sample size estimation and blinded sample size re-estimation, as well as a function for generating
observations from the NB-INAR(1) model, which may be useful for custom simulations. An
overview of the implemented functions is given in Table 2.1.
12
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Table 2.1: Functions implemented in the R-package spass for sample size estimation and blinded
re-estimation within the NB-INAR(1) model.
Function Description
rnbinom.inar1 Generate time series with marginal negative binomial distribution
and autoregressive correlation structure of order one
fit.nb.inar1 Fitting the NB-INAR(1) model on a given data set
n.nb.inar1 Calculate required initial sample size in planning phase
bssr.nb.inar1 Blinded sample size re-estimation on a given data set
test.nb.inar1 Statistical inference for testing treatment effects
All methods are presented with examples of their usage and explanations of parameters, as
required for R-packages, to allow for a simple implementation.
2.2 Gamma Frailty Model
After having explored and used the NB-INAR(1) model for deriving an adaptive design, the
aim was to extend the methods for time trends in the group means. The NB-INAR(1) model
could not have trends in the rates while at the same time maintaining the property of marginal
negative binomial counts, which is why a different model was chosen for this purpose. The
gamma frailty model introduced by Henderson and Shimakura [33] and extended by Fiocco et
al. [19], to account for arbitrary shape parameters, maintains a marginally negative binomial
distributed random variables, while at the same time allowing for arbitrary choices of the
marginal means. This advantage over the NB-INAR(1) model, however, comes at the cost of
less control over the correlation between time points. Observations within the gamma frailty
model are best defined in two steps. First, we assume that for each patient there exists an
unobservable multivariate gamma random variable Zi j = (Z(1)i j , . . . , Z(T)i j ). In this multivariate
random variable, each Z(t)i j follows a gamma distribution with mean one and variance η, i.e.
Z(t)i j ∼ γ(1,η−1). These within-patient frailties are generated such that they are dependent and it
holds that Cor(Z(t)i j , Z
(s)
i j )= a|s−t|. In the second step, we generate the observations X (t)i j by using
the gamma frailty terms as arguments within a Poisson distribution. Conditional on the gamma
frailty, we assume
(2.8) X (t)i j |Z(t)i j ∼ Poisson(λ(t)i Z(t)i j ),
from which it follows that unconditionally on the gamma frailty observations X (t)i j ∼ NB(λ(t)i ,η).
Similarly to the NB-INAR(1) model we now have a marginal negative binomial distribution, with
the difference that the mean of the distribution, i.e. λ(t)i , can also depend on the time point t
and not only the group affiliation i. However, the covariance of two observations from the same
13
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patients given by
(2.9) Cov(X (t)i j , X
(s)





is not autoregressive anymore, but merely has an autoregressive appearance inherited from the
autoregressive within-patient gamma frailty. This property also limits the maximum possible
correlation which can be modeled between observations. For example, assume that λ(t)i = 2 and
η= 0.5 for all t ∈N. Then, the maximum possible correlation between observations, which can be
modeled by setting a = 1, is 0.8.
The main advantage of the gamma frailty model is that, because the means can be chosen
arbitrarily, we can model time trends occurring within a clinical trial while maintaining the
property of marginal negative binomial observations. This allows for different and much more
diverse hypotheses to be tested. By defining a set of regression parameters β= (β1, . . . ,βd) we can
view the means λ(t)i as functions of these regression parameters, i.e. λ
(t)
i = f (t)i (β). For example, if
we assume changing rates over time, we could define exponential trends as
(2.10) f (t)E (β)= exp
(
β1 + (β2 +β3) · t
)
and f (t)C (β)= exp
(
β1 +β2 · t
)
.
This is just one possibility of many thinkable trends, some of which are outlined in more detail
within Asendorf et al. [7]. While this specific trend is motivated by observations in MS clinical
trials, see e.g. Nicholas et al. [49], a general notation for different trends was maintained
throughout the calculations to potentially broaden the application of the presented method.
2.2.1 Statistical Inference
Inference through maximum likelihood is not straightforward within the gamma frailty model. In-
stead of using standard maximum likelihood theory, we estimate parameters using a pseudo likeli-
hood approach with independent working assumption. Estimates for parameters λ= (λ(1)E , . . . ,λ(T)C )







L i j(λ,η|xi j),
where











with respect to β and η. Hereby x= (x(1)E1, . . . , x(T)E1 , . . . , x(T)EnE , . . . , x
(T)
CnC
) and xi j = (x(1)i j , . . . , x(T)i j ) denote
the observed values. The function PNB(x,µ,η) denotes the probability function of a negative
binomial random variable with mean µ and variance µ+µ2/η. The correlation parameter a can
be estimated at a second step by maximizing the pairwise composite likelihood defined as
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where PpairNB (·) denotes the bivariate probability function for counts at different times but on the
same patient. More details on the pairwise probability function are given in Fiocco et al. [19].
Main interest within the gamma frailty model lies in the regression parameters β1, . . . ,βd. For
example, in the presented trend from Equation (2.10) the main interest lies in testing H0 :β3 = 0
vs. H0 : β3 6= 0, because β3 corresponds to the treatment effect. Generally, however, we will be
testing the hypothesis
(2.14) H0 : h(η,β)≥ h0 vs. H1 : h(η,β)< h0,
where h :Rd+1 →R is a twice differentiable and monotone function in all dimensions. Standard






h(η̂, β̂)−h(η,β)) approx∼ N (0,∇(η,β)h(η,β)>H−1JH−1∇(η,β)h(η,β))
for nE,nC →∞ and k = nE/nC constant. The introduced Hessian matrix H and outer gradient
matrix J are defined as







[∇(η,β)(η,β)L i j(λ,η|xi j)]
and







[∇(η,λ)L i j(λ,η|xi j) ·∇(η,λ)L i j(λ,η|xi j)>] .
In standard maximum likelihood theory, using the Fisher information, the Hessian and outer
gradient matrix would coincide, and the term H−1JH−1 would reduce to H−1, i.e. the Fisher
information matrix. However, because the pseudo likelihood does not fully describe the data,
as observations are not independent, the matrices J and H differ and need to be estimated
separately. Estimation of H and J is possible through






∇(η,λ)(η,λ)L i j(η̂, λ̂|xi j)
and






∇(η,λ)L i j(η̂, λ̂|xi j) ·∇(η,λ)L i j(η̂, λ̂|xi j)>.
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With these estimators we can define the test statistic Z, which asymptotically follows a standard
normal distribution
(2.20) Z =pnE +nC ·
h(η̂, λ̂)−h0√
∇(η,λ)h(η̂, λ̂)>(Ĥ−1 ĴĤ−1)∇(η,λ)h(η̂, λ̂)
approx∼ N(0,1).
It is noteworthy that the asymptotics hold for nE,nC →∞ and constant ratio of sample sizes
k = nE/nC. In case of large sample sizes (ni ≥ 100), a simulation study showed that the approx-
imation controls the type I error rate for a set of realistic settings in MS. However, for small
sample sizes, the test statistic showed a simulated type I error rate of 0.03 to 0.04, while the
nominal type I error rate was 0.025. To improve the testing procedure, a method was imple-
mented which estimates the variance σ̂2 =∇(η,λ)h(η̂, λ̂)>(H−1JH−1)∇(η,λ)h(η̂, λ̂) restricted to the
parameter space of the null hypothesis, resulting in an estimate σ̂2r . A simulation study to com-
























High (n = 102 per group)
Low (n = 27 per group)
Figure 2.3: Comparison of type I error rates of the test statistic Z (2.20) using restricted and
unrestricted variance estimates. Each dot represents one simulation setting. Solid lines represent
95% random intervals of simulated type I error rate.
In Figure 2.3 we can see that the unrestricted variance estimates shows higher type I error rates
than the intended significance level of 2.5%, while using the restricted variance estimate controls
the type I error rate even for small sample sizes (ni = 27).
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2.2.2 Blinded Sample Size Re-estimation
Using the normal approximation of Z, a sample size formula was derived which requires infor-
mation on the nuisance parameters and effect size under the alternative. Denoting the shape
parameter, further nuisance parameters and the effect size under alternative as η∗, β∗ and
θ∗ = h(η∗,β∗)− h0, respectively, the sample size required to reject the null hypothesis under




This sample size formula can be used at the planning phase of a clinical trial and also when
re-estimating the sample size. Estimating the nuisance parameters from blinded data was
achieved by assuming the blinded data to be from a mixture distribution of two negative binomial
distributions. Similar to the inference procedure, estimation of the nuisance parameters is done

























assuming the effect θ∗ from the alternative hypothesis being present. In a second step, the
correlation parameter a is estimated through a mixture distribution of the pairwise likelihood







































where estimates β̂ and η̂ are plugged in from the estimation in the first step. The resulting
nuisance parameter estimates are then plugged into the sample size formula from Equation
(2.21) to attain a re-estimated sample size.
2.2.3 Numerical Evaluation of Type I Error Rate and Power
Operational characteristics were investigated for numerous settings realistic for lesion counts in
MS, assuming constant means (i.e. the same setting as investigated by the NB-INAR(1) model)
and the exponential trend described in Equation (2.10). An extensive type I error simulation
(Figure 3 and Figure 4 from Asendorf et al. [7]) over numerous parameters (Table 3 from Asendorf
et al. [7]) revealed no type I error inflation induced by the blinded sample size re-estimation
17
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procedure. For the constant trend, additionally to investigating the type I error for superiority
tests, the type I error for non-inferiority tests was also examined and equally revealed no type I
error inflation attributable to the BSSR.
Power Evaluation of the BSSR procedure revealed, that the BSSR is able to correct the power
in the case of misspecified nuisance parameters. For better readability we first summarize the
results for constant rates and then the results for an underlying exponential trend.
2.2.3.1 Constant Rates
For the sample size of the fixed design, parameters were assumed to be β1 = 0, η= 1 and ρ = 0.5
with an effect size of β2 =−0.3, resulting in a sample size at planning stage of nE = nC = 102 to
attain a power of 80% when testing one-sided at 2.5% significance level. Similar to prior power
simulations, the data was simulated with different nuisance parameters to those assumed, with
nuisance parameters altered sequentially as displayed in Figure 2.4. The intercept rate was
altered between −1.0 and 1.0, the correlation parameter between 0.0 and 1.0, and the shape
parameter between 0.5 and 1.5.
Correlation Parameter Intercept Rate Shape Parameter










Figure 2.4: Simulated power of BSSR and fixed design with true nuisance parameters (x-axis)
altered one by one. Underyling Model: Gamma Frailty, assuming constant rates. Every setting
was simulated 10,000 times.
From Figure 2.4 we can conclude that the blinded sample size re-estimation procedure is able
to correct the sample size under misspecified nuisance parameters accordingly, to reach the
pre-specified power of 80%.
18
2.2. GAMMA FRAILTY MODEL
2.2.3.2 Exponential Trends in Event Rates
In the simulation inspecting the blinded sample size re-estimation procedure with an underlying
exponential trend, parameters for the fixed sample size were assumed to be β1 = 0, β2 = 0, η= 1
and ρ = 0.5, resulting in a required sample size of nC = nE = 229 for rejecting the null hypothesis
with 80% power at 2.5% one-sided significance level, assuming an effect of β3 = 0.05. Data were
simulated with the true treatment effect being present, but nuisance parameters were altered
sequentially. The power comparison between keeping to the initial sample size and switching to
the re-estimated sample size are given in Figure 2.5.
Correlation Parameter Intercept Rate Shape Parameter Slope Rate









Figure 2.5: Simulated power of BSSR and fixed design with true nuisance parameters altered
one by one. Underlying Model: Gamma Frailty, assuming exponential trend. Every setting was
simulated 10,000 times.
In Figure 2.5 we see that the blinded sample size re-estimation procedure is able to correct the
sample size such that the targeted power is reached. Thus, we conclude, that the blinded sample
size re-estimation is capable of correcting the sample size even in the presence of time trends. The
general notation allows for the implementation of flexible time trends as required, broadening
the potential applications.
2.2.4 Software Implementation and Availability of Methods
The presented methods for constant and exponential trends have been implemented within
the R-package spass and made available on CRAN. The package contains functions for sample
size estimation and blinded sample size re-estimation, as well as a function for generating
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observations from the gamma frailty model. An overview of the implemented functions is given
in Table 2.2.
Table 2.2: Functions implemented in the R-package spass for sample size estimation and blinded
re-estimation within the gamma frailty model.
Function Description
rnbinom.gf Generate time series with marginal negative binomial distribution
and unobservable multivariate gamma frailty
fit.nb.gf Fitting the gamma frailty model on a given data set
n.nb.gf Calculate required initial sample size in planning phase
bssr.nb.gf Blinded sample size re-estimation on a given data set during trial
test.nb.gf Statistical inference for testing treatment effects
All methods are presented with examples of their usage and explanations of parameters. Further-
more, input and output of these functions is kept similar to the functions written for the INAR(1)
to allow for model comparisons.
2.3 Negative Binomial Outcomes with Covariates
So far, the presented methods modeled a treatment and possible time effect on the outcomes.
However, treatment effects can also be influenced by further sources, such as baseline observations
or center effects. These effects are usually incorporated by modeling observations conditional on
the covariates. In Zapf et al. [64] two approaches were developed which allow for sample size
estimation and blinded sample size re-estimation of univariate negative binomial counts with
baseline covariates. The statistical model is as follows. Assume we have only one time point, e.g.
the last observation of the trial, and observations of two groups, denoted by X i j, with i = E,C
and j = 1, . . . ,ni. Further we observe a covariate Yi j (or a set of covariates) for each observation
X i j. Then, the conditional model is given by
(2.24) X i j|Yi j ∼ NB(λi j,η)
where λi j and η are fixed parameters. Similarily to the gamma frailty model, the mean λi j can be
defined as a function of regression parameters, usually expressed through a log-link, e.g. for the
case of one covariate λi j = exp
(
β1 +β2 · 1{i=E} +β3 · yi j
)
, where 1{·} denotes the indicator function.
2.3.1 Statistical Inference
For two groups, main interest lies in testing the null hypothesis H0 : c>β = δ vs H1 : c>β 6= δ,
where c is usually chosen to reflect the treatment effect, i.e. c>β=β2 referring to the example
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above. To test this null hypothesis, two different methods were used, namely the likelihood
ratio test statistic and a Wald-type test based on maximum likelihood estimators. Denoting the
observed Fisher information conditional on the covariates as Iβ(β̂, η̂|y), where y= (yE1, . . . ,yCnC )
denotes the collection of all covariates and yi j = (y1, . . . , yp) the covariates of an individual, the
Wald-type test statistic is given by




Furthermore, the employed likelihood ratio test statistic is given by
(2.26) TLR =−2log
 supΩ0 L(β,η|xE1, xE2, . . . , xCnC ,yE1, . . . ,yCnC )
sup
Ω L(β,η|xE1, xE2, . . . , xCnC ,yE1, . . . ,yCnC )
 .
Hereby, L(·, ·|xE1, xE2, . . . , xCnC ,yE1, . . . ,yCnC ) denotes the likelihood function of the negative bi-
nomial regression model. It can be shown that under the null hypothesis, TW
approx∼ N(0,1) and
TLR
approx∼ χ21,1−α as nE →∞ and nC →∞, assuming the ratio nE/nC to be constant. Both test
statistics are commonly used in practice with the Wald-Test being computationally simpler and
the likelihood ratio test having some advantages when computing confidence intervals, as these
are scale invariant and only contain valid values.
2.3.2 Sample Size Estimation
The difficulty when deriving a sample size formula for these test statistics lies in incorporating the
baseline observations. Inference is performed conditional on the baseline observations, however,
as these are not known at the beginning of a trial, the initial sample size calculation needs to be
performed unconditionally of the observed covariates. To achieve this, Lyles et al. [44] proposed
a method which creates an artificial data set, also referred to as expanded data set, which
depends on the distribution of the covariates and outcomes, imitating the unknown covariates.
The observed Fisher Information of the expanded data set can be used for attaining an estimate
of the variance of the effect size, denoted by V̂arED , which in turn is required to calculate the







where λ̂ED = n(δ−θ1)2/V̂arED(θ̂) and χ21(λ̂ED) denotes a chi-squared distributed random variable
with one degree of freedom and non-centrality parameter λ̂ED . By using an iterative method,
such as interval halving, a total sample size n (at fixed allocation ratio k = nE/nC) is calculated
which fulfills the power requirement. Although this method of sample size estimation was shown
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to be adequate, the iterative approach was computationally expensive, consequently limiting
simulation runs. Therefore, a second approach for calculating the sample size was considered,
which is based on the Wald-test. When testing with the Wald-test, the required total sample size
for attaining a specific conditional power under a given alternative θ∗ = c>β∗−δ and significance
level α can be approximated by




In Equation (2.28), the Fisher information is calculated conditional on the covariates. As these
are not known at the planning stage of a clinical trial, the conditional Fisher information is




. This approach gives an
approximation of the sample size required for attaining the unconditional power. More details as
to why this is not an exact approach are given in Section 3.3.2 in Zapf et al. [64]. However, the
presented heuristic was shown to adequately calculate the required sample size in numerical
evaluations.
2.3.3 Blinded Sample Size Re-estimation
Extending the methodology for blinded sample size re-estimation is possible by estimating
nuisance parameters from the blinded data using a mixture approach. The likelihood of a mixture































Within Equation (2.29), the parameter β(θ∗) denotes the regression parameters β with the effect
size under alternative θ∗ fixed. For example, if the null hypothesis is H0 : β2 = 0 and λi j =
exp(β1 +β2 · 1{i=E} +β3 · yi j) then β(θ∗)= (β1,β∗2 ,β3)>. Blinded estimates for parameters β and η
resulting from estimation with the likelihood in Equation (2.29) are then plugged into the sample
size formulas from Equation (2.28) to attain a re-estimated sample size. Under circumstances, it
is also necessary to estimate parameters specific to the distribution of the covariates. Because we
assume that patients were randomized to one of the two groups, parameters corresponding to the
covariate distribution can be estimated by pooling together all observations, regardless of their
group assignment.
2.3.4 Numerical Evaluation of Type I Error Rate and Power
Both methods for blinded sample size re-estimation were evaluated in an extensive simulation.
Furthermore, for the expanded data set approach, the likelihood ratio approach and the Wald-
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type test statistic were compared. The type I error was evaluated for one normally distributed
covariate, assuming an intercept log rate of β1 = 0 a log rate ratio of θ∗ =β2 =−0.2, a covariate
effect of β3 = 2.5 and shape parameter of η= 3. Under these assumptions, the required sample
size for rejecting the null hypothesis H0 :β2 = 0 at 80% power and 5% two-sided significance level
is equal to approximately 380 patient per group. The chosen parameters were comparable to
those observed in a clinical trial in epilepsy by Leppik et al. [41]. For the simulation, true values
of parameters were chosen differently to those of the assumed as displayed in Table 2.3.
Table 2.3: Simulation settings for the comparison of type I error rates between the fixed design
and the blinded sample size re-estimation procedures for univariate negative binomial counts
with covariates.
Parameters Assumed value True values
Intercept log rate β1 0 -1, -0.8, . . . , 1
Log rate ratio β2 -0.2 0
Covariate rate β3 2.5 0, 0.5, . . . , 5
Shape parameter η 3 2, 2.2, . . . , 4
The data was simulated in multiple steps, to best resemble realistic scenarios. First, 25% of the
initial sample size was simulated as complete observations. Second, another 25% of the initial
sample size was simulated, but with observation times uniformly distributed between 0 and
T, i.e. ti
i.i.d.∼ U(0,T), where T denotes the total follow-up time per patient. The combined data
set from the first and second step was taken to perform a sample size re-estimation. Inference
was then performed with sample sizes nWT-FI, nWT-ED and nLR-ED for the fixed design and with
re-estimated sample sizes n̂WT-FI, n̂WT-ED and n̂LR-ED for the blinded sample size re-estimation
design. Hereby, WT-FI refers to the method using the expected Fisher information plugged into
the sample size formula from Equation (2.28), LR-ED to the method using the expanded data set
from Lyles et al. [44] and performing inference with the likelihood ratio test, and WT-ED to the
method using the expanded data set and the Wald-type test statistic for inference. Type I error
rates of all three sample size estimation and re-estimation methods are displayed in Figure 2.6.
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Figure 2.6: Type I error rates of BSSR and fixed design for all possible combinations of parameters
as listed in Table 2.3 while under the null hypothesis. Dashed lines represent 95%-random
intervals for simulated type I error rates. Every setting was simulated 10,000 times.
The type I error simulation did not reveal any notable differences in type I error rates between
the fixed design and the blinded sample size re-estimation procedure for all three procedures.
Additionally to the type I error, the power was also examined in an extensive simulation. For this,
the same simulation settings as in Table 2.3 were considered, with the only difference being that
the true treatment effect was chosen to equal the assumed treatment effect. Figure 2.7 displays
the results from the power simulation for the WT-FI method.
Covariate Rate Intercept Rate Shape Parameter








Figure 2.7: Power simulation of BSSR and fixed design for the WT-FI method, with true nuisance
parameters altered sequentially. Underyling Model: Univariate Negative Binomial Counts with
Covariates. Every setting was simulated 10,000 times.
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For the power simulation, true nuisance parameters were altered one by one and the influence of
the blinded sample size re-estimation procedure examined. In case of a misspecified nuisance
parameters, the blinded sample size re-estimation was capable of correcting the required sample
size to a level required for attaining the pre-specified power. Results of the WT-ED and LR-ED
methods were comparable and are reported in the Appendix of Zapf et al. [64].
2.3.5 Software Implementation and Availability of Methods
The presented methods for sample size estimation and blinded re-estimation with baseline
covariates have been implemented in R and made available as supplementary material to the
publication on figshare under https://doi.org/10.6084/m9.figshare.11973579. An overview
of the implemented functions is given in Table 2.4.
Table 2.4: Functions uploaded as supplementary material within an R-script for sample size
estimation and blinded re-estimation with baseline covariates.
Function Description
wt.fi Initial sample size calculation for the WT-FI method
wt.ed Initial sample size calculation for the WT-ED method
lr.ed Initial sample size calculation for the LR-ED method
sse Initial sample size calculation for all three presented methods
bssr Blinded sample size re-estimation for all three presented methods
Additionally to these R-functions, examples are given to demonstrate their usage and parameters
are explained in detail. Functions for inference are not provided as inference in this case is












The summarized research extends the available methodology for blinded sample size re-estimation
for longitudinal negative binomial counts and univariate negative binomial counts with baseline
covariates. Methods have been shown to not inflate type I error rates, therefore fulfilling regula-
tory requirements. In the presence of the expected treatment effect, but misspecified nuisance
parameters, the methods were able to correct the required sample size to attain the necessary
power for the final analysis.
For longitudinal modeling of negative binomial counts two different models were used, the NB-
INAR(1) model and the gamma frailty model. It was pointed out, that the gamma frailty model
allows for arbitrary means at different time points, therefore allowing for trends within clinical
trials. However, this came at the cost of limiting the modeling correlation between observations.
Specifically, the correlation between observations within the NB-INAR(1) model can lie between
0 and 1, while the maximum correlation in the gamma frailty model depends on the mean
and shape parameter at a given time point. This may not pose a problem in the presence of
intermediate correlation, however, neither model can cope with trends and high correlation
between time points.
For statistical inference, the NB-INAR(1) model used method of moment estimators as an
analytical derivation of the Fisher information was not feasible for a likelihood approach. However,
a numerical approach may be possible and beneficial. Furthermore, from a practical point
of view, data following an NB-INAR(1) or gamma frailty model, can not be analysed using
standard negative binomial regression as implemented in common statistical software. To support
statisticians interested in applying these methods, R-functions were written and made available.
However, these are limited to the cases as described within the publications and extensions, for
example to further trends, are not as easily implemented.
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While missing data due to the recruitment scheme was addressed in all three methods, other
types of missing data were not fully addressed. The procedures as described here can still be
employed for situations where data are missing completely at random or missing at random
[58]. There exists literature on coping with such missingness [4, 45], however, the described
methods have not been implemented and need to be discussed in light of the ICH E9 Addendum
on Estimands and Sensitivity Analysis in Clinical Trials [30].
One crucial point, which is frequently discussed, is the timing of interim analyses at which a
blinded sample size re-estimation is to be performed. While the methods do not give an answer to
an optimal time point, it was shown within Asendorf et al. [6], that conducting the blinded sample
size re-estimation at later time points yields less variable sample size estimates. Therefore, it is
desirable to conduct a blinded sample size re-estimation at the latest possible time point which
allows for a continuation of the recruitment. However, this may bear the risk that the sample size
at interim may already be larger than required. There have been numerous proposals considering
this trade off between low variability of the sample size estimate and risking a too large clinical
trial, with a summary of these given in Section 6 of Friede and Schmidli [25].
Another difficulty when working with time trends in running clinical trials, is defining the type
of underlying trend. The presented methods allow for a very flexible trend definition. However,
assessing the correct underlying trend for a clinical trial is a difficult task, especially in the given
setting where little data is available before the clinical trial. Furthermore, trends with small
effects require a high number of observations to be detected. A possible solution would be to
also allow for switching the underlying trend depending on the goodness of a model fit during
a running trial. However, this would also require a switch of the null hypothesis, which might
influence type I error rates. This aspect has so far not been explored but may pose a substantial
improvement in practice.
Adaptive designs have generally received increased attention over the past decades in all phases of
drug development [59], with the pace of uptake in clinical trials, however, staying well behind that
of statistical literature [50]. Among others, contributing factors are speculated to be unfamiliarity
with advantages and limitations of these procedures within the scientific community, as well as
inadequate implementation of methods [50]. This supports the importance of not only thoroughly
explaining the used methods and their limits, but also to provide an implementation of these,
such that the proposed methods may find their way into clinical trials.
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